Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is one of the best small cap stocks to buy for 10x potential.
On May 4, Stifel lifted the price target on Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to $46 from $45, reaffirming a Buy rating on the shares
It told investors that although modest consensus misses on Revuforj and Niktimvo sales are weighing on the shares, the firm remains “incrementally” more positive and confident in the trajectory of Revuforj. The rating update came after Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) announced its fiscal Q1 2026 results, reporting a total revenue of $64.9 million for the quarter, reflecting a 224% year-over-year increase. Revuforj® net revenue was $48.9 million, showing leadership in menin inhibition and increasing uptake in R/R NPM1m AML.
In addition, Niktimvo™ net revenue reached $55.1 million in the quarter, resulting in Syndax collaboration revenue of $15.9 million. The company also reported that it expects new revumenib real-world, frontline, and post-HSCT maintenance data in fiscal Q2 2026, along with topline data anticipated in fiscal Q4 2026 from Phase 2 trials of axatilimab in IPF and newly diagnosed chronic GVHD. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is involved in the development of cancer therapies, which its products including SyndAccess, Revuforj, Niktimvo, and IncyteCARES.